P3.02c-014 Patients with Recurrence after Resection of Lung Cancer Are Good Candidates for the beyond over Progressive Disease Application of Bevacizumab: Topic: Targeted Therapy

Abstract

The benefit of the continuation of bevacizumab (BEV) beyond over progressive disease (PD) in patients with non-small cell lung cancer (NSCLC) has not been clarified yet. We present our experience of chemotherapy with BEV continuation beyond over PD in patients with recurrent NSCLC after surgery. They were consisted of 19 patients. There were 10 males and 9 females, and their age at surgery was 69±10 (41-85) years old. Lobectomy was done in 18 patients, and segmentectomy in 1. Pathological stage was IA in 5, IB in 3, IIB in 3, IIIA in 5, IIIB in 1, and IV in 2. Recurrence was observed at 630±460 days after surgery. Sixteen patients among them had been received some chemotherapy protocols before usage of BEV for 507±448 days. Performance status before treatment was grade 0 in 11 patients, 1 in 7, and 3 in 1. Chemotherapy was performed intending to continue BEV beyond over PD in these patients. The average number of protocols with BEV was 3±1 (1-5). BEV was used for 1734±413 days. Side effects (≥ grade 2) due to BEV were hypertension in 6 patients, proteinuria in 4, and hemoptysis in 1. Seven patients were died of cancer, and 1 of COPD worsening. Five-year survival rate after surgery, after recurrence, and after initiation of BEV was 81.2%, 45.0%, and 31.2%, and median survival time was 2384 days, 1661 days, and 1105 days, respectively. The majority of patients with operable NSCLC have good performance status. Moreover, we can detect their recurrence in the early periods at most before the symptoms appear, because of the regular examinations. Therefore, these patients are at an advantage that they can receive more chemotherapy protocols. In these selected patients, their prognosis may be prolonged by the continuation of BEV beyond over PD.